ArticleScience immunology2020
Lymph node stromal CCL2 limits antibody responses.
Article in Science immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- A common progenitor gives rise to fibroblastic reticular cells and vascular smooth muscle cells in murine lymph nodes.The Journal of experimental medicine · 2026Article
- Dendritic Cell Organization and Function in Innate and Adaptive Immune Defense Within Lymph Nodes.Immunological reviews · 2026Review
- Functional responses of lymphoid stromal cells to Toll-like receptor stimuliDiscovery immunology · 2026Article
- Interstitial fluid flow in an engineered human lymph node stroma model modulates T cell egress and stromal change.APL bioengineering · 2025Article
- Identification and Mapping of Human Lymph Node Stromal Cell Subsets by Combining Single-Cell RNA Sequencing with Spatial Transcriptomics.European journal of immunology · 2025Article
- Exploring the role of gut microbiota modulation in the long-term therapeutic benefits of early MSC transplantation in MRL/lpr mice.Cellular & molecular biology letters · 2025Article
- Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Exploring the differential functions of circulating follicular helper T and peripheral helper T cells in rheumatoid arthritis based on metabolism patterns.Frontiers in immunology · 2025Article
- KDM6B drives epigenetic reprogramming associated with lymphoid stromal cell early commitment and immune properties.Science advances · 2023Article
- Post-transcriptional checkpoints in autoimmunity.Nature reviews. Rheumatology · 2023Review
- Lessons of Vascular Specialization From Secondary Lymphoid Organ Lymphatic Endothelial Cells.Circulation research · 2023Review
- The advent of immune stimulating CAFs in cancer.Nature reviews. Cancer · 2023Review
- Mesenchymal stem cells empower T cells in the lymph nodes via MCP-1/PD-L1 axis.Cell death & disease · 2022Article
- Imaging viral infection in vivo to gain unique perspectives on cellular antiviral immunity.Immunological reviews · 2022Review
- The RNA-binding protein IMP2 drives a stromal-Th17 cell circuit in autoimmune neuroinflammation.JCI insight · 2022Article
- Lymphatic endothelial sphingosine 1-phosphate receptor 1 enhances macrophage clearance via lymphatic system following myocardial infarction.Frontiers in cardiovascular medicine · 2022Article
- Compartmentalized multicellular crosstalk in lymph nodes coordinates the generation of potent cellular and humoral immune responses.European journal of immunology · 2021Review
- Stromal cell-derived DEL-1 inhibits Tfh cell activation and inflammatory arthritis.The Journal of clinical investigation · 2021Article
- Review
- Lymph node fibroblastic reticular cells steer immune responses.Trends in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
Nonhematopoietic stromal cells in lymph nodes such as fibroblastic reticular cells (FRCs) can support the survival of plasmablasts and plasma cells [together, antibody-forming cells (AFCs)]. However, a regulatory function for the stromal compartment in AFC accumulation has not been appreciated. Here, we show that chemokine ligand 2 (CCL2)-expressing stromal cells limit AFC survival. FRCs express high levels of CCL2 in vessel-rich areas of the T cell zone and the medulla, where AFCs are located. FRC CCL2 is up-regulated during AFC accumulation, and we use lymph node transplantation to show that CCL2 deficiency in BP3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.